Pharmacotherapeutic follow-up to patients with type 2 diabetes mellitus of the I-4 Nauta Health Center
DOI:
https://doi.org/10.15381/ci.v25i2.24863Keywords:
pharmacotherapeutic follow-up (PFU), drug related problems (DRP), pharmaceutical intervention, diabetes mellitus type 2Abstract
Diabetes mellitus is a chronic disease that is increasing worldwide and in Peru; so that patients suffering from this disease may present problems related to medications. The objective of this research was to provide a Pharmacotherapeutic Follow-up (SFT) service to older adult patients diagnosed with type 2 diabetes mellitus; at the same time identify the type of problems and the causes that generate the Problems Related to Medications (PRM); as well as pharmaceutical intervention (FI) and pharmacotherapeutic compliance of patients for prevention. It is a prospective, descriptive, and longitudinal study. Using the tools of the Dáder methodology to carry out pharmacotherapeutic follow-up (SFT), the evaluation of compliance and knowledge was carried out using the Morisky-Green test; Patients with type 2 diabetes mellitus, who were treated at the I-4 Nauta Health Center, were evaluated for three months. 13 patients were included in the study. In total, 13 drug-related problems (DRPs) were detected, with 1 DRP (53.8%) being the most frequent, followed by 4 DRPs (15.4%). Inadequate conservation (23.1%) and non-compliance with treatment (30.8%) were identified as the most frequent causes. Through the SFT, the type and causes that generate drug-related problems (PRM) were identified, and at the same time it was observed that 61.5% corresponded to need, 23.1% to effectiveness, and 15.4% to safety. It was concluded that the optimization of the SFT is positively influenced in the improvement of the patient’s health status.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Patricia Raygada-Ramirez, Norma Ramos-Cevallos
This work is licensed under a Creative Commons Attribution 4.0 International License.
LOS AUTORES RETIENEN SUS DERECHOS:
- Los autores retienen sus derechos de marca y patente, y tambien sobre cualquier proceso o procedimiento descrito en el artículo.
- Los autores retienen el derecho de compartir, copiar, distribuir, ejecutar y comunicar públicamente el articulo publicado en la Revista Ciencia e Investigación (por ejemplo, colocarlo en un repositorio institucional o publicarlo en un libro), con un reconocimiento de su publicación inicial en la Revista Ciencia e Investigación.
- Los autores retienen el derecho a hacer una posterior publicación de su trabajo, de utilizar el artículo o cualquier parte de aquel (por ejemplo: una compilación de sus trabajos, notas para conferencias, tesis, o para un libro), siempre que indiquen la fuente de publicación (autores del trabajo, revista, volumen, numero y fecha).
